Entinostat deal expands Eddingpharm's China oncology portfolio
This article was originally published in Scrip
Following a string of deals this year by Chinese pharma firms looking to license in technology and products from foreign partners, the Hong Kong-based drug marketing company Eddingpharm has acquired rights in China and several other Asian markets to Syndax Pharmaceuticals' lead candidate entinostat.
You may also be interested in...
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.